share_log

Diffusion Pharmaceuticals Analyst Ratings

Benzinga Analyst Ratings ·  Aug 16, 2022 18:30
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/16/2022 38.28% HC Wainwright & Co. → $9.5 Upgrades Neutral → Buy
11/17/2020 HC Wainwright & Co. Downgrades Buy → Neutral
11/17/2020 HC Wainwright & Co. Downgrades Buy → Neutral
12/18/2019 -49.05% HC Wainwright & Co. $10 → $3.5 Reiterates → Buy
03/21/2018 -81.8% HC Wainwright & Co. → $1.25 Initiates Coverage On → Buy

Diffusion Pharmaceuticals Questions & Answers

What is the target price for Diffusion Pharmaceuticals (DFFN)?

The latest price target for Diffusion Pharmaceuticals (NASDAQ: DFFN) was reported by HC Wainwright & Co. on August 16, 2022. The analyst firm set a price target for $9.50 expecting DFFN to rise to within 12 months (a possible 38.28% upside). 1 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Diffusion Pharmaceuticals (DFFN)?

The latest analyst rating for Diffusion Pharmaceuticals (NASDAQ: DFFN) was provided by HC Wainwright & Co., and Diffusion Pharmaceuticals upgraded their buy rating.

When is the next analyst rating going to be posted or updated for Diffusion Pharmaceuticals (DFFN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Diffusion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Diffusion Pharmaceuticals was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.

Is the Analyst Rating Diffusion Pharmaceuticals (DFFN) correct?

While ratings are subjective and will change, the latest Diffusion Pharmaceuticals (DFFN) rating was a upgraded with a price target of $0.00 to $9.50. The current price Diffusion Pharmaceuticals (DFFN) is trading at is $6.87, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment